BackAssembly Biosciences Overview

Assembly Biosciences Receivables

Track Assembly Biosciences's receivables ($820K) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Receivables
$822000.00

Peer trimmed avg / median

Loading

Assembly Biosciences Receivables History

Loading

Assembly Biosciences vs. peers: Receivables Comparison

Loading

Assembly Biosciences Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Assembly Biosciences (ASMB) FAQ

Assembly Biosciences's receivables stands at $820K as of June 2026. In the prior-year period, the figure was $0. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Assembly Biosciences reported $820K in receivables versus $0 a year earlier. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

In the prior-year period, the figure was $0. Sustained growth in receivables can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Assembly Biosciences's receivables evolved across reporting periods, while the comparison chart places ASMB next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, receivables is commonly used to spot outliers. Assembly Biosciences's reading of $820K is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.